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Experimental spinal cord injury (SCI) causes a morphological and functional deterioration
of the heart, in which the renin–angiotensin system (RAS) might play a role. The recently
discovered non-canonical axis of RAS with angiotensin-(1–7) and its receptor Mas,
which is associated with cardioprotection could be essential to prevent damage to the
heart following SCI. We investigated the cardiac consequences of SCI and the role of
Mas in female wild-type (WT, n = 22) and mice deficient of Mas (Mas−/−, n = 25) which
underwent spinal cord transection at thoracic level T4 (T4-Tx) or sham-operation by
echocardiography (0, 7, 21, and 28 days post-SCI), histology and gene expression
analysis at 1 or 2 months post-SCI. We found left ventricular mass reduction with
preserved ejection fraction (EF) and fractional shortening in WT as well as Mas−/− mice.
Cardiac output was reduced in Mas−/− mice, whereas stroke volume (SV) was reduced
in WT T4-Tx mice. Echocardiographic indices did not differ between the genotypes.
Smaller heart weight (HW) and smaller cardiomyocyte diameter at 1 month post-
SCI compared to sham mice was independent of genotype. The muscle-specific E3
ubiquitin ligases Atrogin-1/MAFbx and MuRF1 were upregulated or showed a trend
for upregulation in WT mice at 2 months post-SCI, respectively. Angiotensinogen gene
expression was upregulated at 1 month post-SCI and angiotensin II receptor type 2
downregulated at 2 month post-SCI in Mas−/− mice. Mas was downregulated post-
SCI. Cardiac atrophy following SCI, not exacerbated by lack of Mas, is a physiological
reaction as there were no signs of cardiac pathology and dysfunction.
Keywords: renin–angiotensin system, cardiac atrophy, atrogenes, sympathetic nervous system, fibrosis
INTRODUCTION
Cardiovascular dysfunction is one of the leading causes of morbidity and mortality in both acute
and chronic stages of spinal cord injury (SCI) (Weaver et al., 2012). The threefold higher risk of
heart disease in people with SCI (Cragg et al., 2013) is caused by the development of cardiovascular
risk factors, but might also be caused by direct changes in the heart. Acute heart failure is evident
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immediately after SCI in autopsy as well as in experimental
animals as electron micrographs show signs of calcium
excitotoxicity following massive norepinephrine release (Sharov
and Galakhin, 1984). Recent studies in a chronic thoracic-level 3
(T3) rat model of SCI showed sustained cardiac atrophy, systolic
dysfunction, reduced contractility, as well as a trend for increased
myocardial collagen deposition (West et al., 2014; Poormasjedi-
Meibod et al., 2019). A meta-analysis of 22 studies with 474
participants found reductions to left ventricle (LV) stroke volume
(SV), end-diastolic volume, and LV mass in high-thoracic SCI
patients vs. able-bodied. However, in contrast to the experimental
data, hearts of SCI patients seem to adapt relatively well to the
situation post-SCI as ejection fraction (EF) and diastolic function
(Williams et al., 2019) as well as contractility (Driussi et al., 2014)
remain preserved. Further research on experimental SCI models
could shed light on the discrepancies between human situation
and pre-clinical models.
Reduced cardiac weight (atrophy) following cervical or high-
thoracic SCI, a consistent finding between studies, is caused by
loss of sympathetic innervation to the heart and/or unloading
following SCI. In thoracic injuries above T6, control of brainstem
over vasculature of the lower body is lost. However, the
proportion of loss of the sympathetic input to the heart and
the vasculature of the upper thoracic segments depends from
the exact level of the SCI. For example, after transection of the
spinal cord at T4 (T4-Tx) the heart would lose approx. three-
fourth of its sympathetic input, majority of which comes from
stellate ganglia (Strack et al., 1988; Lujan and Dicarlo, 2014).
Cardiac atrophy is mediated by activation of the ubiquitin–
proteasome system and the autophagy–lysosomal machinery
(Zaglia et al., 2013; Poormasjedi-Meibod et al., 2019). Its
pathological or physiological nature remains to be determined.
The renin–angiotensin system (RAS) which usually regulates
blood pressure and fluid balance was proposed to be involved
in pathological atrophy of the heart following SCI (Poormasjedi-
Meibod et al., 2019). This is an interesting possibility, as RAS
affects hemodynamics after SCI as we have recently shown
(Jarve et al., 2018, 2019), and generates peptide hormones
with great impact on the heart (Bader, 2013). The recently
discovered non-canonical axis of the RAS including angiotensin-
(1–7) which acts via the G protein-coupled receptor (GPCR)
Mas exert mostly opposite functions to the classical RAS (Bader
et al., 2018) and the Ang-(1–7)-Mas axis has been shown
to play a key role in the maintenance of the structure and
function of the heart (Santos et al., 2006). For example, an acute
treatment with Ang-(1–7) before ischemia/reperfusion injury led
to significant recovery of heart function following ischemia in
hearts isolated from spinal cord injured rats (Benter et al., 2011).
The main actions of Ang-(1–7) in the heart are regulation of
genes involved in fibrosis in cardiac fibroblasts via Mas, NO-
releasing, antioxidative, NO-increasing, direct anti-hypertrophic
effects on cardiomyocytes and regulation of endothelial function
(Santos et al., 2006; Rabelo et al., 2008; Bader, 2013). Ang-(1–
7)-Mas receptor axis attenuates cardiac remodeling and fibrosis
in post-myocardial infarction (Wang et al., 2017). Based on
beneficial effects of Mas, we hypothesized that mice lacking
Mas have much poorer outcome in the heart when investigated
by echocardiography, immunohistochemistry, and molecular
biology methods.
MATERIALS AND METHODS
Mice and SCI
Experiments were conducted according to the National Institutes
of Health Guide for the Care and Use of Laboratory Animals,
and the protocols were approved by the local Animal Care
and Use Committee from Berlin LAGeSo (G0132/14). All mice
were housed in groups of four to six animals in cages with
nesting material, mouse lodges and open access to water and
food, at 23◦C with a 12 h/12 h circadian cycle. Experiments
were performed using wild type (WT, Mas+/+) vs. Mas−/−
female mice both on C57Bl/6 N background (Walther et al.,
1998), weighing 20–25 g, and at about 3 months of age. The
experimental plan is depicted under Supplementary Figure 1.
Spinal cord injury was done under intraperitoneal Ketamine
(100 mg/kg) – Xylazine (10 mg/kg) anesthesia in combination
with isoflurane (1.5–1.8%) inhalation as described previously
(Järve et al., 2019). Briefly, a dorsal midline incision was made
in the superficial muscle overlying the C7–T3 vertebrae. The
dura was opened at the T2–T3 intervertebral gap and the spinal
cord was completely transected at thoracic spinal cord segment
4 using microscissors. Complete transection was confirmed by
pulling a needle twice between the rostral and caudal spinal
cord stumps. Gelfoam was placed above spinal cord to achieve
hemostasis. The muscle and skin were closed with absorbable
sutures (Vicryl, 4–0, Ethicon GmbH). Animals received warmed
saline (1 ml, s.c.), recovered and were kept in heated cages
(30◦C) for the rest of the experiments. For analgesia mice were
treated with Carprofen (4 mg/kg, s.c.) directly after operation
and next day with 12 h interval, if necessary longer. The bladder
was manually emptied three times daily for the whole duration
of the experiment.
Echocardiographic Studies
Two-dimensional echocardiography imaging was performed
under isoflurane anesthesia 1 day before and 7, 21, and
28 days post-injury/sham-surgery (dpi) using the Vevo 700
(VisualSonics, Toronto, Canada) equipped with scan head MS-
400 with transmit frequency of 30 MHz. Anesthesia was induced
with isoflurane 3% and maintained with (1.6 vol% isoflurane/air).
Body temperature was maintained through a heating pad at
37◦C. Images were acquired for further off-line analysis by
an operator of Max Delbrück Center for Molecular Medicine
Animal Phenotyping Platform blinded for genotype. LV end-
diastolic and end-systolic diameter (LVIDd, LVIDs), EF, SV, and
heart rate (HR) were determined by tracing of endocardial and
epicardial borders and majors in end-diastole and in end-systole
in the parasternal long axis view. LV end-diastolic and end-
systolic posterior wall thickness (PWTd, PWTs) and anterior
wall (interventricular septal wall) thickness (IVSd, IVSs) were
determined by tracing in end-diastole and in end-systole in
the parasternal short axis view. Following parameters were
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calculated: fractional shortening (FS, %) = 100 × ((LVIDd –
LVIDs)/LVIDd); cardiac output (CO, ml/min) = SV × HR/1000;
LV mass = 1.053× ((LVIDd+ LVPWd+ IVSd)3 – LVIDd3).
Quantitative RT-PCR
Hearts were halved so that the apex-facing part was processed
further for RNA isolation and real-time qPCR analysis and
the upper part was used for histology. For RNA isolation with
Trizol and FastPrep beads the manufacturer’s instructions
were followed. Reverse transcription was performed with
2 mg total RNA digested by incubation with 1 ml DNase I
(Roche) using Moloney murine leukemia virus. Real-time
PCR was performed with a QuantStudio 5 Real-Time PCR
System (Thermo Fisher Scientific, Waltham, MA, United States)
according to the manufacturers’ recommendations by using
SYBR green. Each cDNA sample was tested in triplicate,
and the expression level of each gene was normalized to
the hypoxanthine–guanine phosphoribosyltransferase (Hprt)
level. Following primers were used: Agtr1a forward: 5′-
CCATTGTCCACCCGATGAAG-3′, Agtr1a reverse: 5′-TGC
AGGTGACTTTGGCCAC-3′, Agtr2 forward: 5′-CAATCTGGCT
GTGGCTGACTT-3′, Agtr2 reverse: 5′-TGCACATCACAGGT
CCAA AGA-3′, angiotensinogen forward: 5′-TGTGACAGGGTG
GAAGATGA-3′, reverse: 5′-CAGGCA GCTGAGAGAAACCT-
3′, Mas forward: 5′-AGGGTGACTGACTGAGTTTGG-3′, re-
verse: 5′-GAAGGTAAGAGGACAGGAGC-3′, MAFbx for-
ward: 5′-AGTGAGGACCGGCTACTGTG-3′, reverse: 5′-GA
TCAAACGCTTGCGAATCT-3′, Murf1 forward: 5′-TGACAT
CTACAAGCAGGAGTGC-3′, reverse: 5′-TCGTCTTCGTGTTC
CTTGC-3′, Hprt forward: 5′-GTAATGATCAGTCAACGGGGG
AC-3′, Hprt reverse: 5′-CCAGCAAGCTTGCAACCTTAACCA-
3′. The fold change was determined using the 2−1
1C(t) method.
HE and Picro Sirius Red Staining
Upper halves of the hearts were incubated in KCl for 10 min,
fixed for 48 h in 4% paraformaldehyde in buffered saline (pH
7.4) at 4◦C, washed, dehydrated, embedded in paraffin, sectioned
at 5 µm with a rotary microtome (Microm; Thermo Fisher
Scientific), placed on SuperFrost Plus slides (Thermo Fisher
Scientific), and stored at RT until use. For picro Sirius red
staining paraffin sections were deparaffinized, rehydrated, and
stained by incubation with picro-Sirius red solution (0.1% Sirius
red F3B in saturated aqueous solution of picric acid) for 1 h
at room temperature. After two washes with acidified water
(0.5% glacial acetic acid in tap water), sections were dehydrated
in three changes of 100% ethanol, cleared using xylene,
and coverslipped using Eukitt (ORSAtec GmbH, Bobingen,
Germany). Four non-consecutive sections with hematoxylin–
eosin (HE) and Sirius red staining per mouse were analyzed using
an inverted microscope (BZ-9000; Keyence, Osaka, Japan). For
immunostainings, pretreated paraffin sections were blocked for
30 min with 10% normal donkey serum in PBS, followed by
incubation with the primary antibody polyclonal rabbit Murf1
(1:100, self-generated, Thomas Sommer, MDC, Germany) and
goat anti-MAFxb (1:100; ab92281, Abcam) in PBS overnight at
4◦C. The next day, sections were washed with PBS three times
for 15 min and incubated with the secondary antibody solution
in PBS for 2 h at room temperature. Sections were washed
again three times with PBS and cover slipped using Vectashield
(Vecta Laboratories, Burlingame, CA, United States) mounting
medium containing DAPI. Images were taken using an inverted
microscope (BZ-9000; Keyence, Osaka, Japan).
Quantification of Cardiomyocyte
Diameter
Wheat germ agglutinin (WGA) staining was performed by
incubating heart sections with WGA + Al488 conjugate (1:300)
(Thermo Fisher, Invitrogen, United States) for 20 h, washed
three times with PBS for 10 min each and cover slipped using
Vectashield (Vecta Laboratories, Burlingame, CA, United States)
mounting medium containing DAPI. To evaluate cardiomyocyte
diameter images were taken using an inverted microscope (BZ-
9000) and 610-980 cardiomyocytes per group were analyzed
using BZ-II Analyzer software (Keyence).
Statistics
Results are presented as mean ± SEM. Data were analyzed
statistically using Prism 5 software (GraphPad Software,
San Diego, CA, United States) and SPSS (IMB Analytics).
Echocardiography data were analyzed by three-way repeated
measures (RM) ANOVA with time (pre, 7, 21, and 28 dpi)
as one within-subject factor and genotype (WT, Mas−/−) and
surgery (sham, T4-Tx) as two between subject factors. Once
no significant three-factor interaction was detected, two-way
RM ANOVA with Bonferroni posttest was performed. Heart
weight (HW) data and gene expression data were analyzed
by three-way ANOVA incorporating the following variables:
genotype (WT, Mas−/−) and surgery (sham, T4-Tx) and time
(1 month and 2 months post-surgery). Once no significant
three-factor interaction was detected, one-way ANOVA with
Bonferroni posttest was performed. Student’s t-test was applied
for comparisons between individual pairs of means once
normality was demonstrated. Significance for all tests was
assumed when p < 0.05.
RESULTS
Echocardiography: SCI Leads to
Reduced LV Mass With Preserved FS
and EF
Spinal cord injury caused a reduction in the LVIDd and LVIDs
at 21 and 28 dpi vs. pre-injury and vs. sham in WT mice
(Figures 1A,B, p < 0.05, two-way RM ANOVA). Mas−/−
mice showed only a reduction in these indices when sham
mice were compared (Figures 1A,B, p < 0.01, two-way RM
ANOVA). IVSd was significantly reduced at 28 dpi vs. pre-
injury in Mas−/− mice (Figure 1C, p < 0.01, one-way ANOVA)
and at 7 dpi vs. sham in WT mice (p < 0.05, two-way RM
ANOVA). PWTd at 7 dpi was in WT sham higher than in
WT T4-Tx (Figure 1E). Consequently, LV mass was reduced at
all time points following SCI (Figure 1G, p < 0.05, one-way
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FIGURE 1 | Echocardiography pre- and post-surgery in WT and Mas−/− sham-operated and T4-Tx mice. Structural parameters: (A) left ventricular internal
diameter during diastole (LVIDd) and (B) LVID during systole (LVIDs), (C) interventricular septum thickness at diastole (IVSd) and (D) at systole (IVSs), (E) posterior
wall thickness at diastole (PWTd), (F) at systole (PWTs), and (G) left ventricular mass (LV mass). Functional parameters: (H) stroke volume (SV), (I) heart rate, (J)
cardiac output (CO), (K) fractional shortening (FS), and (L) ejection fraction (EF). Significant three-way repeated measures ANOVA results are presented above the
graphs, two-way repeated measures ANOVA with Bonferroni posttests *P < 0.05, **P < 0.01, ***P < 0.001 sham vs. T4-Tx; one-way ANOVA with Bonferroni
posttests #P < 0.05, ##P < 0.01, ###P < 0.001 pre vs. post-injury. Data are displayed as mean ± SEM.
ANOVA), except it was not significant at 7 dpi following SCI
in Mas−/− mice. Progression of LV structural changes such as
the reduction in LVIDd, LVIDs, LV mass in injured Mas−/−
mice was not significantly different compared to injured WT
mice (two-way RM ANOVA, interaction of time and genotype, all
p > 0.0984). Although PWTd, PWTs, IVSd, and IVSs of Mas−/−
mice seemed to be differentially regulated compared to WT
(Figures 1C–F), two-way RM ANOVA of injured mice found no
significant interaction of time and genotype for these parameters
(all p > 0.0522). Functional changes included SV reduction post-
SCI, HR increase at 21 and 28 dpi vs. pre-injury in the WT
mice (Figures 1H,I, p < 0.05, one-way ANOVA) resulting in
unchanged CO (Figure 1J). In contrast, SV was significantly
reduced only at 28 dpi (two-way RM ANOVA, p < 0.05) and
HR did not change significantly in the Mas−/− mice, but CO was
reduced significantly at 28 dpi vs. pre-injury (p < 0.05, one-week
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FIGURE 2 | Cardiac atrophy and smaller cardiomyocyte diameter post-SCI. Heart weight (HW) (A) and its ratio with tibia length (B), but not its ratio with body weight
(HW/BW) (C) were reduced in injured mice compared to sham mice at 1 and 2 months post-SCI. (D) Cardiomyocyte diameter was smaller in injured mice.
(E) Representative images of cardiomyocytes in a LV section stained with wheat germ agglutinin-Alexa Fluor 488 conjugate (green cell boundaries) and DAPI (blue
nuclei). Scale bar is 50 µm. Three-way ANOVA significant main effects presented above the graphs (A–C), ∗ (∗∗/∗∗∗)P < 0.05 (0.01/0.001) using Student’s t-test.
Data are displayed as mean ± SEM.
ANOVA). Dynamics in SV was not different between injured
Mas−/− and WT mice (two-way RM ANOVA, p = 0.5289),
whereas dynamics of HR was (p = 0.0140). SCI caused no change
in FS and EF (Figures 1K,L). They were lower in Mas−/− mice
at 28 dpi, but difference to WT was not significant (two-way
RM ANOVA, p = 0.1901). Three-way RM ANOVA performed on
all the parameters revealed no significant interaction of surgery
(sham, T4-Tx), genotype (WT, Mas−/−) and time (pre, 7, 21, and
28 dpi) (all F-values < 1.456, p > 0.234).
Reduced Cardiac Weight and
Cardiomyocyte Diameter Following SCI
Spinal cord injured mice had significantly smaller HW and
HW/tibia length ratios at 1 month post-SCI, confirming
the findings of echocardiography (Figures 2A,B, p < 0.05,
one-week ANOVA). The decrease of HW was proportional
to the body weight (BW) reduction as demonstrated
by the unchanged HW/BW ratio (Figure 2C). HW and
HW/tibia ratios remained significantly smaller in mice
with T4-Tx at 2 months post-SCI compared to respective
sham mice (Figures 2D,E, p < 0.05, one-way ANOVA).
WT values at 2 months were significantly smaller vs.
1 month post-SCI (p < 0.01, Student’s t-test). The
HW/BW ratio remained unchanged also at 2 months
post-SCI. Histological analysis of the cardiomyocyte
diameter at the mid-ventricular level revealed a significant
decrease in the SCI groups vs. sham groups to similar
extent in both genotypes (Figures 2D,E, p < 0.001,
Student’s t-test).
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FIGURE 3 | No histological alteration in the heart post-SCI. Hematoxylin-eosin (A–F) and picro Sirius red staining (G–L) of heart paraffin sections from
sham-operated and spinal cord-injured WT and Mas−/− mice 1 and 2 months post-SCI. Scale bar: 500 µm.
No Signs of Cardiac Pathology Post-SCI
The myocardium of SCI mice presented normal histology,
absence of cardiomyocyte necrosis, infiltration of cells
(Figures 3A–F). We found no interstitial as well as perivascular
fibrosis assessed by picro Sirius red staining at 1 and 2 months
post-SCI (Figures 3G–L).
Atrogene and RAS Expression Post-SCI
Cardiac atrophy is usually accompanied by the upregulation
of atrogenes such as Muscle Atrophy F-box (MAFbx) and
RING-finger protein-1 (Murf1). Gene expression of MAFbx was
upregulated, but this difference reached significance only at
2 months post-SCI in WT mice (Figure 4A, p < 0.05, Student’s
t-test). Murf1 showed only a trend for upregulation at 2 months
post-injury in WT mice (Figure 4B). Angiotensinogen was
upregulated at 1 month post-SCI in Mas−/− mice (Figure 4C,
p < 0.05, Student’s t-test). Ang II receptor 1a (Agtr1a) was not
significantly regulated (Figure 4D), whereas Ang II receptor 2
(Agtr2) was downregulated at 2 months post-SCI in Mas−/−mice
(Figure 4E, p < 0.001, Student’s t-test). Mas was downregulated
2 months post-SCI in WT mice (Figure 4F, p < 0.01, Student’s
t-test). Immunohistochemistry of Murf1 and MAFbx showed
increased immunofluorescence in injured mice compared to
sham at 2 months post-SCI (Figures 4G–N, respectively).
DISCUSSION
Our study is the first to examine the effect of SCI on murine
heart using echocardiography, histology, and gene expression
analysis in WT and Mas-deficient mice. We found that T4-Tx
SCI caused persistent cardiac atrophy with significant reduction
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FIGURE 4 | Gene expression of atrogenes and RAS members in the heart of 1-month and 2 months post-SCI in WT and Mas−/− mice. Atrogene MAFbx was
upregulated in WT mice at 2 months (A), whereas Murf1 remained unchanged in Mas−/− (B). Angiotensinogen was upregulated significantly in Mas−/− mice at
1 months post-SCI (C), Agtr1a was not significantly regulated (D), Agtr2 was downregulated significantly in Mas+/+ and Mas−/− mice at 2 months post-SCI (E) and
Mas was downregulated in control Mas+/+ mice at 2 months post-SCI (F). Three-way ANOVA significant interactions and main effects presented above the graphs,
∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005 Student’s t-test. Representative images of immunostaining of Murf1 (G–J) and MAFxb (K–N) in the heart in sham and injured
mice 2 months post-SCI. Scale bar 50 µm.
in LV mass, HW, and cardiomyocyte diameter at 1 month post-
injury, reduced HW at 2 months post-SCI, preserved EF and FS,
no fibrosis nor pathological signs in the hearts of injured mice
at 1 and 2 months post-SCI. Differential effects of SCI in WT
compared to Mas−/− mice included reduced IVSd and PWTd at
7 dpi vs. sham, as well as increased HR at 21 and 28 dpi in injured
WT mice, whereas Mas−/− mice had reduced CO at 28 dpi.
The impact of Mas-deficiency on heart following high-
thoracic SCI was modest, taking into account that this receptor
plays positive role in many cardiac conditions (Bader, 2013).
For example, Mas is an important regulator of vascular tonus
being involved in the vasodilator effect of Ang-(1–7), bradykinin,
acetylcholine (Peiro et al., 2007; Peiró et al., 2013), and estradiol
(Sobrino et al., 2010, 2017) which is beneficial in the hypertensive
situation. After T4-Tx, however, drastic hypotension occurs
in mice (Jarve et al., 2018), due to the loss of sympathetic
vasoconstrictor input to the vascular beds below the injury. In this
situation, Mas-deficiency rather than Mas-mediated vasodilation
might be advantageous. Indeed, Mas-deficient mice have less
severe hypotension in the acute phase of SCI (Jarve et al., 2018).
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This favorable effect might occur because of higher vascular tonus
and/or higher CO in Mas−/− mice. In this study, CO of Mas−/−
mice was higher at acute phase compared to WT mice (t-test,
p = 0.0481 at 7 dpi) indicating that CO might contribute to
this effect. In contrast, in chronic phase of SCI (28 dpi), CO of
Mas−/− mice decreased significantly meaning that at this stage
higher vascular tonus in these mice must exist as hypotension was
comparable between the phenotypes. This is not accompanied by
hyperreactivity of the vasculature to phenylephrine and Ang II
in Mas−/− mice or in its isolated mesenteric vessels (Jarve et al.,
2018). CO depends on SV and HF. As SV was similarly decreased
at 28 dpi in both genotypes, lower CO at 28 dpi in Mas−/− mice
is due to lower HF in these mice, a finding which matches well
with our previous telemetry study (Jarve et al., 2018).
Echocardiography Data in Mouse SCI
Model Is in Good Agreement With
Clinical Data
Our findings of cardiac atrophy (LV mass reduction ca. 22% in
the present study and 25% in patients) with preserved function
agrees well with SCI patient data (Williams et al., 2019), in which
the atrophy is often considered as a physiological adaption, e.g.,
to preserve function (Sharif et al., 2017). Also a pre-clinical
study in rats at 35 dpi agrees well with our data (West et al.,
2014). The same group observed however reduced EF and FS
at 3 months post-SCI (Poormasjedi-Meibod et al., 2019), which
we cannot exclude to happen also in our model at a later
time point. Cardiac atrophy occurs also in healthy persons after
2 weeks of bed-rest and reaches a 15% decrease in LV mass index
after 12-week-bed rest (Perhonen et al., 2001). Even in some
proportion of cachexia patients significant loss of LV mass was
not associated with specific cardiac abnormalities (Florea et al.,
2002) indicating that it is possible to have atrophy and maybe
altered but not compromised function of the heart. Furthermore,
in our T4-Tx model, the heart would be deprived from at least
a proportion of sympathetic innervation to the LV (Strack et al.,
1988), also resulting in loss of trophic support and consequently
leading to cardiac atrophy (Zaglia et al., 2013), which was not
accompanied by dysfunction.
Could activation of the RAS contribute to cardiac atrophy?
The role of Ang II and its receptor Agtr1a in skeletal muscle
atrophy is well established (Burks et al., 2011; Cabello-Verrugio
et al., 2012). Mas activation on the other hand counteracts
skeletal muscle atrophy induced by Ang II (Cisternas et al.,
2015), disuse (Morales et al., 2016), and cancer (Murphy et al.,
2019). SCI with profound hypotension activates the RAS as its
main mediator Ang II is significantly elevated (Frankel et al.,
1972; Groothuis et al., 2010; Poormasjedi-Meibod et al., 2019)
and expression of its receptor Agtr1a is increased in the heart
post-SCI (Poormasjedi-Meibod et al., 2019). Together with our
findings of elevated angiotensinogen mRNA post-SCI (at 1-month
post-SCI in Mas−/− mice) and a trend for Agtr1a upregulation
(at 2 months post-SCI in WT mice) a potential atrophy-inducing
environment might be present in the myocard, on top of cardiac
unloading and loss of cardiac sympathetic innervation. We have
previously demonstrated that Mas−/− mice present more severe
atrophy of the gastrocnemius and plantaris muscles at 28 days
post-T4-Tx (Järve et al., 2019). This prompted us to assume in
this study that Mas−/− mice would suffer more from cardiac
atrophy post-SCI. However, our results showed that absence
of Mas is not aggravating cardiac atrophy. This would not
necessarily exclude the possibility that an infusion of Ang-(1–
7) would have a positive effect on cardiac atrophy. However, in
the light of the downregulation of Mas determined in this study a
prospective vasodilation effect of such treatment post-SCI would
be difficult to achieve.
We did not observe any fibrosis in the hearts of injured
mice nor did we find any other histological indices of end-organ
damage in the heart. For example, long-term unloading after
heterotopic heart transplantation was associated with decreased
function and increased fibrosis (Oriyanhan et al., 2007). It has
been suggested that the cardiac unloading itself might produce
cardiac remodeling post-SCI (e.g., increased fibrosis) (Lujan and
Dicarlo, 2014). Further studies with longer time points could be
necessary to reveal this effect.
We used only female mice in our study. It is also important to
analyze male mice, because hormonal systems such as estradiol
influence the vascular system and thus the effects we observed in
the knockout mice could be influenced by this. It has been shown
that estradiol in physiological levels can cause vasodilation in the
presence of Mas (Sobrino et al., 2017). Conversely, in Mas−/−
mice probably this vasodilation effect of estradiol is impaired.
It was not surprising to find some regulation in the
ubiquitin/proteasome system (UPS) genes. It would be necessary
to investigate autophagy in future studies, as it is involved
in cardiac atrophy following SCI (Poormasjedi-Meibod et al.,
2019) and is dominating in unloading-induced atrophy, whereas
activation of UPS is most important in starvation−induced
cardiac atrophy (Cao et al., 2013).
CONCLUSION
T4-Tx SCI leads to significant atrophy of the murine heart.
In light of preserved EF and FS as well as in the absence of
signs of end-organ damage, there is no reason to consider the
murine heart compromised or dysfunctional at 1-month post-
SCI, at least in rest. Furthermore, lack of Mas, is not detrimental
to cardiac structure or function in the early chronic phase of
SCI. Future studies with longer time frame could show how the
changes progress over time and whether other members of the
RAS are involved.
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